BioSight
Companies
Karyopharm Therapeutics Inc. logo

KPTI

NASDAQNEWTON, MA
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a commercial-stage oncology company developing small molecule XPO1 inhibitors, with its lead approved product XPOVIO (selinexor) currently marketed in the U.S. for multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. The company is advancing selinexor in late-stage clinical trials for myelofibrosis and endometrial cancer, with Phase 3 data expected in 2026, while also developing the next-generation XPO1 inhibitor eltanexor for additional oncology indications.

Price history not yet available for KPTI.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar